FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
When U.S. health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of voices: doctors and pharmacists with deep financial ties to the burgeon



















